Zacks Investment Research upgraded shares of NYMOX PHARMACTL (NYMX) from NEUTRAL to OUTPERFORM on October 30, 2012, with a target price of $7.80.
Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is based in St Laurent, Canada.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NYMOX PHARMACTL (NYMX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment